An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...